Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Tanja Fens, Guiling Zhou, Maarten J. Postma, Eugène P. van Puijenbroek & Job F.M. van Boven. (2021) Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?. Expert Opinion on Pharmacotherapy 22:7, pages 923-935.
Read now
Read now
Bhavesh Lakhotia, Ronan Mahon, Florian S Gutzwiller, Andriy Danyliv, Ivan Nikolaev & Praveen Thokala. (2020) Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 787-797.
Read now
Read now
Articles from other publishers (2)
Dhvani Shah, Maurice Driessen, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs & Afisi S. Ismaila. (2018) Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. Cost Effectiveness and Resource Allocation 16:1.
Crossref
Crossref
Wouter Poortinga, Sarah E Rodgers, Ronan A Lyons, Pippa Anderson, Chris Tweed, Charlotte Grey, Shiyu Jiang, Rhodri Johnson, Alan Watkins & Thomas G Winfield. (2018) The health impacts of energy performance investments in low-income areas: a mixed-methods approach. Public Health Research 6:5, pages 1-182.
Crossref
Crossref